Involvement of substance P and the NK-1 receptor in human pathology

Amino Acids

Volumn 46, Issue 7, 2014, Pages 1727-1750

  Muñoz, Miguel ^a,b   Coveñas, Rafael ^c  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Human pathology; Molecular bases; NK 1 receptor; NK 1 receptor antagonists; Substance P

Indexed keywords

APREPITANT; CASOPITANT; CJ 11 974; CJ 12 255; CP 122 721; CP 122 721 1; CP 96 345; CP 99 994; EZLOPITANT; FOSAPREPITANT; GR 205 171; L 703 606; L 732 138; L 733 060; L 754 030; L 759 274; L 822 429; LANEPITANT; LY 303 870; LY 686 017; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; RP 67 580; RPR 100 893; SPANTIDE; SR 140 333; SR 140 333B; SUBSTANCE P; UNCLASSIFIED DRUG; VOFOPITANT; WIN 51 708;

ABORTION; ALCOHOLISM; ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLESTASIS; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL STRESS; GENE SILENCING; HEPATITIS; HEPATOBLASTOMA; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KERATITIS; LYME DISEASE; MEASLES; MENINGITIS; MENINGOCOCCOSIS; MIGRAINE; MOOD DISORDER; MYOCARDITIS; NEOPLASM; NERVE DEGENERATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; OSTEOSARCOMA; PAIN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PNEUMOCOCCAL MENINGITIS; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; RECEPTOR BLOCKING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEIZURE; SEPSIS; TOOTH PAIN; TOXIC HEPATITIS; TRANQUILIZING ACTIVITY; UPREGULATION; VIRUS INFECTION; VOMITING; ANIMAL; BACTERIAL INFECTION; GENETICS; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALCOHOLISM; ANIMALS; BACTERIAL INFECTIONS; DEPRESSION; HUMANS; INFLAMMATION; MIGRAINE DISORDERS; NEOPLASMS; PAIN; RECEPTORS, NEUROKININ-1; SEIZURES; STRESS, PSYCHOLOGICAL; SUBSTANCE P; VIRUS DISEASES; VOMITING;

EID: 84903635625     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1736-9     Document Type: Article

References (144)

1. Abidi MH, Tageja N, Ayash L, Abrams J, Ratanatharathorn V, Al- Kadhimi Z, Lum L, Cronin S, Ventimiglia M, Uberti J (2012) Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial. Support Care Cancer 20:2363-2369
2. Angulo JA, McEwen BS (1994) Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res Brain Res Rev 19:1-28 (Pubitemid 24024082)
3. Annunziata P, Cioni C, Toneatto S, Paccagnini E (1998) HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. AIDS 12:2377-2385 (Pubitemid 28558595)
4. Arck PC, Merali FS, Stanisz AM, Stead RH, Chaouat G, Manuel J, Clark DA (1995) Stress-induced murine abortion associated with substance P-dependent alteration in cytokines in maternal uterine decidua. Biol Reprod 53:814-819
5. Armstrong DM, Pickel VM, Joh TH, Reis DJ, Miller RJ (1981) Immunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in the area postrema and medial nucleus tractus solitarius of rat brain. J Comp Neurol 196:505-517 (Pubitemid 11094111)
6. Azzari C, Rossi ME, Resti M, Caldini AL, Lega L, Galli L, Fico E, Vierucci A (1992) Changed levels of substance P and somatostatin in HIV-positive children. Pediatr Med Chir 14:577-581
7. Baek MN, Jung KH, Halder D, Choi MR, Lee BH, Lee BC, Jung MH, Choi IG, Chung MK, Oh DY, Chai YG (2010) Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice. Neurosci Lett 475:124-128
8. Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G (2003) Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 305:31-39 (Pubitemid 36373833)
9. Bang R, Biburger M, Neuhuber WL, Tiegs G (2004) Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage. J Pharmacol Exp Ther 308:1174-1180 (Pubitemid 38263995)
10. Bardelli C, Amoruso A, Manzetti E, Fresu LG, Valsesia R, Zeppegno P, Brunelleschi S (2013) Recurrent major depressive disorder: imbalance of neurokinin (NK)-1 and NK-2 receptor expression in monocytes. Pharmacol Res 68:24-30
11. Berger M, Neth O, Ilmer M, Garnier A, Salinas-Martín MV, de Agustín Asencio JC, von Schweinitz D, Kappler R, Muñoz M (2014) Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol (in press)
12. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136-142 (Pubitemid 34155124)
13. Borsook D, Upadhyay J, Klimas M, Schwarz AJ, Coimbra A, Baumgartner R, George E, Potter WZ, Large T, Bleakman D, Evelhoch J, Iyengar S, Becerra L, Hargreaves RJ (2012) Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. Drug Discov Today 17:964-973
14. Bountra C, Bunce K, Dale K, Gardner C, Jordan C, Twissell D, Ward P (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 249:R3-R4 (Pubitemid 23326901)
15. Brener S, González-Moles MA, Tostes D, Esteban F, Gil-Montoya JA, Ruiz-Avila I, Bravo M, Muñoz M (2009) A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res 29:2323-2329
16. Carletti R, Corsi M, Melotto S, Caberlotto L (2005) Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci 21:1712-1718 (Pubitemid 40646616)
17. Castro-Obregón S, del Río G, Chen SF, Swanson RA, Frankowski H, Rao RV, Stoka V, Vesce S, Nicholls DG, Bredesen DE (2002) A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. Cell Death Differ 9:807-817
18. Chauhan VS, Sterka DG Jr, Gray DL, Bost KL, Marriott I (2008) Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol 180:8241-8249
19. Chauhan VS, Kluttz JM, Bost KL, Marriott I (2011) Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol 186:7255-7263
20. Connor HE (1998) Clinical evaluation of a novel, potent, CNS penetrating NK-1 receptor antagonist in the acute treatment of migraine. Cephalalgia 18:392
21. Cuello AC, Kanazawa I (1978) The distribution of substance P immunoreactive fibres in the rat central nervous system. J Comp Neurol 178:129-156
22. de Lanerolle NC, Brines M, Williamson A, Kim JH, Spencer DD (1992) Neurotransmitters and their receptors in human temporal lobe epilepsy. Epilepsy Res 7:235-250
23. Diener HC (2003) RPR100893 Study Group. RPR100893, a substance- P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23:183-185
24. Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB (1998) The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 64:562-568 (Pubitemid 28531601)
25. Dunzendorfer S, Meierhofer C, Wiedermann CJ (1998) Signaling in neuropeptide-induced migration of human eosinophils. J Leukocyte Biol 64:828-834 (Pubitemid 28555398)
26. Ebner K, Singewald N (2006) The role of substance P in stress and anxiety responses. Amino Acids 31:251-272 (Pubitemid 44537051)
27. Ebner K, Rupniak NM, Saria A, Singewald N (2004) Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 101:4280-4285 (Pubitemid 38405920)
28. Ebner K, Sartori SB, Singewald N (2009) Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 15:1647-1674
29. Esteban F, González-Moles MA, Castro D, Martín-Jaén MM, Redondo M, Ruiz-Avila I, Rosso M, Muñoz M (2009) Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54:258-260
30. Fackler OT, Grosse R (2008) Cell motility through plasma membrane blebbing. J Cell Biol 181:879-884 (Pubitemid 351846821)
31. Feistritzer C, Clausen J, Sturn DH, Djanani A, Gunsilius E, Wiedermann CJ, Kahler CM (2003) Natural killer cell functions mediated by the neuropeptide substance P. Regul Pept 116:119-126 (Pubitemid 37352922)
32. Fong TM, Yu H, Strader CD (1992) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP-67,580. J Biol Chem 267:25668-25671 (Pubitemid 23013958)
33. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731-742 (Pubitemid 36618051)
34. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergström M, Pich EM, Nilsson LG, Bani M, La° ngström B, Fredrikson M (2005) Cerebral blood flow changes after treatment of social phobia with the eurokinin-1 antagonist GR-205,171, citalopram, or placebo. Biol Psychiatry 58:132-142 (Pubitemid 41008130)
35. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K (2007) Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 128:209-214 (Pubitemid 46367415)
36. Gallai V, Sarchielli P, Flofidi A, Francceschini M, Codini M, Trequattrini A, Palumbo R (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384-390
37. Garant DS, Iadarola MJ, Gale K (1986) Substance P antagonists in substantia nigra are anticonvulsant. Brain Res 382:372-378 (Pubitemid 16001745)
38. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319:1536-1539 (Pubitemid 351398184)
39. Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of human during migraine headache. Ann Neurol 28:183-187 (Pubitemid 20244522)
40. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17:785-790 (Pubitemid 27505105)
41. Goldstein DJ, Wang O, Gitter BD, Iyengar S (2001) Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 24:16-22 (Pubitemid 32176476)
42. González-Moles MA, Mosqueda-Taylor A, Esteban F, Gil-Montoya JA, Díaz-Franco MA, Delgado M, Muñoz M (2008) Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol 44:1127-1133
43. Graham GJ, Stevens JM, Page NM, Grant AD, Brain SD, Lowry PJ, Gibbins JM (2004) Tachykinins regulate the function of platelets. Blood 104:1058-1065 (Pubitemid 39038026)
44. Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF (2006) Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 176:2535-2540 (Pubitemid 44665982)
45. Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E (2005) Broad-spectrum G protein- coupled receptor antagonist, [D-Arg1, DTrp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65:2738-2745 (Pubitemid 40490075)
46. Harrison S, Geppetti P (2001) Substance P. Int J Biochem Cell Biol 33:555-576 (Pubitemid 32510811)
47. Harrowe G, Mitsuhashi M, Payan DG (1990) Measles virus-substance P receptor interactions. Possible novel mechanism of viral fusion. J Clin Invest 85:1324-1327 (Pubitemid 20123781)
48. Hegde A, Zhang H, Moochhala SM, Bhatia M (2007) Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J Leukoc Biol 82:678-685 (Pubitemid 47367160)
49. Hegde A, Tamizhselvi R, Manikandan J, Melendez AJ, Moochhala SM, Bhatia M (2010a) Substance P in polymicrobial sepsis: molecular fingerprint of lung injury in preprotachykinin-A -/- mice. Mol Med 16:188-198
50. Hegde A, Koh YH, Moochhala SM, Bhatia M (2010b) Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights. Int J Inflam 2010:601098
51. Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Gunberg SM (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27:5363-5369
52. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17:338-343 (Pubitemid 29022412)
53. Hill R (2000) NK1 (substance P) receptor antagonists: why are they not analgesic in humans? Trends Pharmacol Sci 21:244-246
54. Ho WZ, Cnaan A, Li YH, Zhao H, Lee HR, Song L, Douglas SD (1996) Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res Hum Retroviruses 12:195-198 (Pubitemid 26054163)
55. Hökfelt T, Pernow B, Nilsson G, Wetterberg L, Goldstein M, Jeffcoate SL (1978) Dense plexus of substance P-immunoreactive nerve terminals in eminentia medialis of the primate hypothalamus. Proc Natl Acad Sci USA 74:1013-1015 (Pubitemid 8298503)
56. Hökfelt T, Broberger C, David Xu Z-Q, Sergeyev V, Ubink R, Diez M (2000) Neuropeptides: an overview. Neuropharmacology 39:1337-1356
57. Hökfelt T, Pernow B, Wahren J (2001) Substance P: a pioneer amongst neuropeptides. J Intern Med 249:27-40 (Pubitemid 32147090)
58. Holzer P (1988) Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24:739-768
59. Janelsins BM, Mathers AR, Tkacheva OA, Erdos G, Shufesky WJ, Morelli AE, Larregina AT (2009) Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood 113:3017-3026
60. Jang JH, Nam TS, Paik KS, Leem JW (2004) Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat. Neurosci Lett 360:129-132 (Pubitemid 38479750)
61. Kalinichev M, Bradford A, Bison S, Lucas A, Sartori I, Garbati N, Andreetta F, Bate S, Austin NE, Jones DN, Read KD, Alvaro G, Large CH (2010) Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat. Epilepsia 51:1543-1551
62. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S (2006) Lack of efficacy of the substance P (neurokinin-1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59:216-223 (Pubitemid 43208967)
63. King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G (2001) Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 24:101-107 (Pubitemid 32152070)
64. Ko FJ, Chiang CH, Liu WJ, Chiang W (1991) Somatostatin, substance P, prolactin and vasoactive intestinal peptide levels in serum and cerebrospinal fluid of children with seizure disorders. Gaoxiong Yi Xue Ke Xue Za Zhi 7:391-397
65. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Halle JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlsson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645 (Pubitemid 28435572)
66. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y (2004) Demonstration of the efficacy and safety of a novel substance P (NK-1) receptor antagonist in major depression. Neuropsychopharmacology 29:385-392 (Pubitemid 38180456)
67. Lai JP, Douglas SD, Rappaport E, Wu JM, Ho WZ (1998) Identification of a delta isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes. J Neuroimmunol 91:121-128 (Pubitemid 28545252)
68. Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De Veerman M, de Felipe C, Hunt SP, Thielemans K, Joos GF, Pauwels RA (1999) Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol 29:3815-3825
69. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231-238 (Pubitemid 39244363)
70. Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A (1992) The nonpeptide tachykinin antagonist, CP-96.345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 105:527-530
71. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NFkappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159:4952-4958 (Pubitemid 127471032)
72. Lieb KL, Treffurth Y, Hamke M, Akundi RS, von Kleinsorgen M, Fiebich BL (2003) Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. J Neurochem 86:69-76 (Pubitemid 36753847)
73. Liu H, Cao Y, Basbaum AI, Mazarati AM, Sankar R, Wasterlain CG (1999) Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci USA 96:12096-12101 (Pubitemid 29502864)
74. Lotz M, Vaughan JH, Carson DA (1988) Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241:1218-1221
75. Maeno H, Kiyama H, Tohyama M (1993) Distribution of the substance P (NK1) receptor in the central nervous system. Mol Brain Res 18:43-58
76. Mai JK, Stephens PH, Hopf A, Cuello AC (1986) Substance P in the human brain. Neuroscience 17:709-739 (Pubitemid 16131267)
77. Makhortova NR, Askovich P, Patterson CE, Gechman LA, Gerard NP, Rall GF (2007) Neurokinin-1 enables measles virus transsynaptic spread in neurons. Virology 362:235-244 (Pubitemid 46617700)
78. Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, Douglas SD (2010) Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS 24:2789-2796
79. Marriott I, Mason MJ, Elhofy A, Bost KL (2000) Substance P activates NF-kappaB independent of elevations in intracellular calcium in murine macrophages and dendritic cells. J Neuroimmunol 102:163-171
80. Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F (2009) Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinasedependent mechanism. J Biol Chem 284:9280-9289
81. Muñoz M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17:504-516
82. Muñoz M, Coveñas R (2011) NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 18:1820-1831
83. Muñoz M, Coveñas R (2013a) Involvement of substance P and the NK-1 receptor in cancer. Peptides 48:1-9
84. Muñoz M, Coveñas R (2013b) Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf 12:673-685
85. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 48:2775-2781 (Pubitemid 351261233)
86. Muñoz M, Rosso M, Robles-Frías MJ, Salinas-Martín MV, Coveñas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90:1259-1269
87. Muñoz M, González-Ortega A, Rosso M, Robles-Frías MJ, Carranza A, Salinas-Martín MV, Coveñas R (2012) The substance P/Neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 38:318-325
88. Muñoz M, Berger M, Rosso M, González-Ortega A, Carranza A, Coveñas R (2014) Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Int J Oncol 44:137-146
89. Murtra P, Sheasby AM, Hunt SP, de Felipe C (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405:180-183 (Pubitemid 30313535)
90. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N (1994) Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 347:249-274 (Pubitemid 24273427)
91. Nikolaus S, Huston JP, Hasenohrl RU (1999a) The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. NeuroReport 10:2293-2296 (Pubitemid 29367926)
92. Nikolaus S, Huston JP, Hasenohrl RU (1999b) Reinforcing effects of neurokinin substance P in the ventral pallidum: mediation by the tachykinin NK1 receptor. Eur J Pharmacol 370:93-99 (Pubitemid 29185094)
93. Nikolaus S, Huston JP, Hasenohrl RU (2000) Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P. Neurosci Lett 283:37-40 (Pubitemid 30145491)
94. Nio DA, Moylan RN, Roche JK (1993) Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J Immunol 150:5281-5288 (Pubitemid 23180641)
95. Norman B (1998) A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK-1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 18:407
96. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201:167-180 (Pubitemid 39305095)
97. Olver IN, Grimison P, Chatfield M, Stockler MR, Toner GC, Gebski V, Harrup R, Underhill C, Kichenadasse G, Singhal N, Davis ID, Boland A, McDonald A, Thomson D, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2013) Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Suport Care Cancer 21:1561-1568
98. Pascual DW, Bost KL (1990) Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunology 71:52-56 (Pubitemid 20296071)
99. Pfister HW, Kümpfel T, Koedel U (1995) Involvement of substance P in pial arteriolar vasodilatation during pneumococcal meningitis in the rat. NeuroReport 6:1301-1305
100. Piedimonte G, Rodriguez MM, King KA, McLean S, Jiang X (1999) Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 277:L831-L840 (Pubitemid 29522651)
101. Puneet P, Hegde A, Ng SW, Lau HY, Lu J, Moochhala SM, Bhatia M (2006) Preprotachykinin-A gene products are key mediators of lung injury in polymicrobial sepsis. J Immunol 176:3813-3820 (Pubitemid 43364030)
102. Quartara L, Maggi CA (1998) The tachykinin NK1 receptor part II: distribution and pathophysiological roles. Neuropeptides 32:1-49 (Pubitemid 28167857)
103. Ramalho R, Almeida J, Beltrão M, Pirraco A, Costa R, Sokhatska O, Guardão L, Palmares C, Guimarães JT, Delgado L, Moreira A, Soares R (2013) Substance P antagonist improves both obesity and asthma in a mouse model. Allergy 68:48-54
104. Reid MS, Herrera-Marschitz M, Hökfelt T, Ohlin M, Valentino KL, Ungerstedt U (1990a) Effects of intranigral substance P and neurokinin A on striatal dopamine release-I. Interactions with substance P antagonists. Neuroscience 36:643-658 (Pubitemid 20282179)
105. Reid MS, Herrera-Marschitz M, Kehr J, Ungerstedt U (1990b) Striatal dopamine and glutamate release: effects of intranigral injections of substance P. Acta Physiol Scand 140:527-537
106. Reinhardt R (1998) Comparison of neurokinin-1 antagonist, L-745,030, to placebo, acetaminophen and ibuprofen in the dental pain model. Clin Pharmacol Ther 63:168
107. Ripley TL, Gadd CA, De Felipe C, Hunt SP, Stephens DN (2002) Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 43:1258-1268 (Pubitemid 36084436)
108. Rittner HL, Lux C, Labuz D, Mousa SA, Achäfer M, Stein C, Brack A (2007) Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception. Anesthesiology 107:1009-1017 (Pubitemid 350175684)
109. Robinson P, Garza A, Moore J, Eckols TK, Parti S, Balaji V, Vallejo J, Tweardy DJ (2009) Substance P is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med 2:76-86
110. Robinson P, Garza A, Weinstock J, Serpa JA, Goodman JC, Eckols KT, Firozgary B, Tweardy DJ (2012) Substance P causes seizures in neurocysticercosis. PLoS Pathog 8:e1002489
111. Rodríguez FD, Coveñas R (2011) Targeting opioid and neurokinin-1 receptors to treat alcoholism. Curr Med Chem 18:4321-4334
112. Rosenberg ZF, Fauci AS (1990) Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol Today 11:176-180 (Pubitemid 20118082)
113. Rosenberg ZF, Fauci AS (1991) Immunopathogenesis of HIV infection. FASEB J 5:2382-2390 (Pubitemid 21905785)
114. Ruff MR, Wahl SM, Pert CB (1985) Substance P receptor-mediated chemotaxis of human monocytes. Peptides 6:107-111 (Pubitemid 16211115)
115. Rupniak NM, Carlson EC, Boyce S, Webb JK, Hill RG (1996) Enantioselective inhibition of the formalin paw late phase by the NK-1 receptor antagonist L-733,060 in gerbils. Pain 67:189-195 (Pubitemid 26319652)
116. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A (2000) Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413-1421 (Pubitemid 30249203)
117. Rupniak NM, Calrson EJ, Webb JK, Harrison T, Porsolt RD, Roux S, de Felipe C, Hunt SP, Oates B, Wheeldon A (2001) Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497-508 (Pubitemid 33152274)
118. Sachais BS, Snider RM, Lowe JA 3rd, Krause JE (1993) Molecular basis for the species selectivity of the substance P antagonist CP- 96,345. J Biol Chem 268:2319-2323 (Pubitemid 23057845)
119. Saffroy M, Beaujouan JC, Torrens Y, Besseyre J, Bergstrom L, Glowinski J (1988) Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain. Peptides 9:227-241 (Pubitemid 19260226)
120. Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of singledose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-bind, placebo-controlled phase 3 trial. Ann Oncol 24:1067-1073
121. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G (2000) Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain 84:389-395 (Pubitemid 30074242)
122. Samsam M, Coveñas R, Csillik B, Ahangari R, Yajeya J, Riquelme R, Narváez JA, Tramu G (2001) Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; A possible neurophysiological and neuroanatomical link to generalized head pain. J Chem Neuroanat 21:161-169 (Pubitemid 32324239)
123. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G (2012) Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 13:1020-1024
124. Sartori SB, Burnet PWJ, Sharp T, Singewald N (2004) Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain. Neuropharmacology 46:1177-1183 (Pubitemid 38529941)
125. Schratzberger P, Reinisch N, Prodinger WM, Kahler CM, Sitte BA, Bellmann R, Fischer-Colbrie R, Winkler H, Wiedermann CJ (1997) Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. J Immunol 158:3895-3901 (Pubitemid 127488749)
126. Scicchinato R, Biennenstock J, Stanisz AM (1988) In vivo immunomodulation by the neuropeptide substance P. Immunology 63:733-735
127. Shibata H, Mio M, Tasaka K (1985) Analysis of the mechanism of histamine release induced by substance P. Biochem Biophys Acta 846:1-7 (Pubitemid 15012789)
128. Shirayama Y, Mitsushio H, Takashima M, Ichinawa H, Takahashi K (1996) Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 739:70-78 (Pubitemid 26387364)
129. Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:388-393 (Pubitemid 30055841)
130. Sperk G, Wieser R, Widmann R, Singer EA (1986) Kainic acid induced seizures: changes in somatostatin, substance P and neurotensin. Neuroscience 17:1117-1126 (Pubitemid 16080100)
131. Sporn MB (1996) The war on cancer. Lancet 347:1377-1381
132. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA (2010) Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 5:e10968
133. Tebas P, Tuluc F, Barret JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD (2011) A randomized, placebo controlled, double masked phase Ib study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One 6:e24180
134. Teodoro FC, Tronco Júnior MF, Zampronio AR, Martini AC, Rae GA, Chichorro JG (2013) Peripheral substance P and neurokinin- 1 receptors have a role in inflammatory and neuropathic orofacial pain models. Neuropeptides 47:199-206
135. Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 7:e34138
136. Thorsell A, Schank JR, Singley E, Hunt SP, Heilig M (2010) Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. Psychopharmacology 209:103-111
137. Trivedi M, Bergasa NV (2010) Serum concentrations of substance P in cholestasis. Ann Hepatol 9:177-180
138. Twardy BS, Channappanavar R, Suvas S (2011) Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions. Invest Ophthalmol Vis Sci 52:8604-8613
139. Unger T, Rascher W, Schuster C, Pavlovitch R, Schömig A, Dietz R, Ganten D (1981) Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin. Eur J Pharmacol 71:33-42 (Pubitemid 11112563)
140. Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF (2008) Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. Neuropsychopharmacology 33:1919-1928 (Pubitemid 351832600)
141. Wolf SS, Moody TW, Quirion R, O'Donohue TL (1985) Biochemical characterization and autoradiographic localization of central SP receptor using [125I] physalaemin. Brain Res 332:299-307 (Pubitemid 15108000)
142. Yu J, Cadet JL, Angulo JA (2002) Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 83:613-622 (Pubitemid 35231815)
143. Zachrisson O, Lindefors N, Brené S (1998) A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acidinduced seizure activity. Brain Res Mol Brain Res 60:291-295 (Pubitemid 28466593)
144. Ziche M, Morbidelli L, Pacini M, Gepetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264-278 (Pubitemid 20327679)